Abstract
The PML protein is best known for its role as a tumor suppressor for acute promyelocytic leukemia. Both PML and the key Wnt signaling regulator AXIN regulate p53-dependent apoptosis in response to DNA damage. However, how the two major tumor suppressors coordinate with each other is unknown, and the molecular components orchestrating the PML-induced apoptosis remain enigmatic. Here we show that AXIN interacts with PML in vivo, and further that AXIN, PML and p53 form a ternary complex. Exposure to genotoxic signals including UV and doxorubicin induces AXIN to enter into the nucleus where it colocalizes with PML in the nuclear bodies. Domain-mapping experiments revealed that the C-terminal region (aa 597–832) of AXIN is responsible for its interaction with PML. AXIN fails to activate p53 in PML−/− cells, and conversely, PML is unable to activate p53 in AXIN-null SNU475 cells. Consistently, knockdown with respective siRNAs revealed that AXIN and PML depend on each other to elevate p53-Ser-46 phosphorylation and to induce apoptosis after treatment with genotoxins. Moreover, we found that dominant-negative mutants of PML blocked AXIN-induced p53 activation, and that AXIN promotes PML sumoylation, a modification necessary for PML functions. Our finding has thus provided a new avenue for understanding the mechanism by which PML activates p53 and exerts its role as a tumor suppressor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ascoli CA, Maul GG . (1991). Identification of a novel nuclear domain. J Cell Biol 112: 785–795.
Bernardi R, Papa A, Pandolfi PP . (2008). Regulation of apoptosis by PML and the PML-NBs. Oncogene 27: 6299–6312.
Bruno S, Ghiotto F, Fais F, Fagioli M, Luzi L, Pelicci PG et al. (2003). The PML gene is not involved in the regulation of MHC class I expression in human cell lines. Blood 101: 3514–3519.
de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G et al (2004). PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13: 523–535.
de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A . (1991). The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675–684.
D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. (2002). Homeodomain interacting protein kinase-2 phosphorylates p53 at Ser-46 and mediates apoptosis. Nat Cell Biol 4: 11–19.
Eskiw CH, Dellaire G, Bazett-Jones DP . (2004). Chromatin contributes to structural integrity of PML bodies through a SUMO-1-independent mechanism. J Biol Chem 279: 9577–9585.
Goddard AD, Borrow J, Freemont PS, Solomon E . (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371–1374.
Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L et al. (2007). TIP60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063–1067.
Gresko E, Ritterhoff S, Sevilla-Perez J, Roscic A, Fröbius K, Kotevic I et al. (2009). PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 28: 698–708.
Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al. (2000). The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730–736.
Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al. (2004). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269–279.
Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W et al. (2002). Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4: 1–10.
Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. (2009). Tankyrase inhibition stabilizes Axin and antagonizes Wnt signalling. Nature 461: 614–620.
Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221–234.
Jin LH, Shao QJ, Luo W, Ye ZY, Li Q, Lin SC . (2003). Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer 107: 696–699.
Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV et al. (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663–674.
Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET . (1998). Identification of three major sentrinization sites in PML. J Biol Chem 273: 26675–26682.
Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A et al. (2001). Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor a degradation. J Exp Med 193: 1361–1371.
Lamond AI, Earnshaw WC . (1998). Structure and function in the nucleus. Science 280: 547–553.
Le X-F, Yang P, Chang K-S . (1996). Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem 271: 130–135.
Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H et al. (2009). Axin determines cell fates by controlling p53 activation threshold upon DNA damage. Nat Cell Biol 11: 1128–1134.
Li Q, Wang X, Wu X, Rui Y, Liu W, Wang J et al. (2007). Daxx cooperates with the axin/HIPK2/p53 complex to induce cell death. Cancer Res 67: 66–74.
Möller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Dröge W et al. (2003). PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63: 4310–4314.
Nikuseva Martić T, Pećina-Slaus N, Kusec V, Kokotović T, Musinović H, Tomas D et al. (2010). Changes of AXIN-1 and beta-catenin in neuroepithelial brain tumors. Pathol Oncol Res 16: 75–79.
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862.
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207–210.
Pearson M, Pelicci PG . (2001). PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20: 7250–7256.
Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de Thé H . (1998). PML induces a novel caspase-independent death process. Nat Genet 20: 259–265.
Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. (2007). MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 25: 739–750.
Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W et al. (2004). Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 23: 4583–4594.
Salomoni P, Ferguson BJ, Wyllie AH, Rich T . (2008). New insights into the role of PML in tumour suppression. Cell Res 18: 622–640.
Salomoni P, Khelifi AF . (2006). Daxx: death or survival protein? Trends Cell Biol 16: 97–104.
Salomoni P, Pandolfi PP . (2002). The role of PML in tumor suppression. Cell 108: 165–170.
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T et al. (2000). AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245–250.
Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP . (2006). The mechanisms of PML-nuclear body formation. Mol Cell 24: 331–339.
Shima Y, Shima T, Chiba T, Irimura T, Pandolfi PP, Kitabayashi I et al. (2008). PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. Mol Cell Biol 28: 7126–7138.
Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP . (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523–527.
Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al. (1998a). Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547–1551.
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. (1998b). PML is essential for multiple apoptotic pathways. Nat Genet 20: 266–272.
Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J et al. (2008). Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10: 812–824.
Wu Q, Hu H, Lan J, Emenari C, Wang Z, Chang KS et al. (2009). PML3 orchestrates the nuclear dynamics and function of TIP60. J Biol Chem 284: 8747–8759.
Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry III WL et al. (1997). The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90: 181–192.
Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH . (2003). Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115: 177–186.
Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP . (2000a). Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748–2752.
Acknowledgements
We thank Dr PP Pandolfi for the gift of the wild-type MEF cells and PML−/− MEF cells, Dr Qiao Wu for the RARE luciferase reporter. This work was supported by grants from MOST (nos. 2009CB522200 and 2006AA02A303). This work was also supported by grants from National Natural Science Foundation of China (nos. 30730025, 30921005, 30500273, 30770454, 30970613), the National Basic Research Program of MOST (no. 2007CB914602), the Natural Science Foundation of Fujian Province (nos. 2008J0109 and 2009J06021) and the program for NCET.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Li, Q., He, Y., Wei, L. et al. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene 30, 1194–1204 (2011). https://doi.org/10.1038/onc.2010.499
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.499
Keywords
This article is cited by
-
TRIMming p53’s anticancer activity
Oncogene (2016)
-
The function, regulation and therapeutic implications of the tumor suppressor protein, PML
Cell & Bioscience (2015)
-
Role of the nucleus in apoptosis: signaling and execution
Cellular and Molecular Life Sciences (2015)
-
PML-mediated signaling and its role in cancer stem cells
Oncogene (2014)